Insiders trading at MeiraGTx plc
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus és Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
What does MeiraGTx plc do?
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
What does MeiraGTx plc's logo look like?
MeiraGTx plc executives and stock owners
MeiraGTx plc executives and other stock owners filed with the SEC include:
-
Alexandria Forbes,
President, Chief Executive Officer, Director -
Richard Giroux,
Chief Financial Officer, Chief Operating Officer -
Dr. Alexandria Forbes,
CEO, Pres & Director -
Martin Indyk,
Independent Director -
Richard Brian Giroux B.A.,
COO & CFO -
Stuart Naylor,
Chief Development Officer -
Dr. Stuart Naylor Ph.D.,
Chief Devel. Officer -
Nicole Seligman,
Independent Director -
Keith Harris,
Independent Chairman of the Board -
Neil Mendoza,
Independent Director -
Joel Marcus,
Independent Director -
Arnold Levine,
Independent Director -
Thomas Shenk,
Independent Director -
Ellen Hukkelhoven,
Independent Director -
Elizabeth Broder,
Investor Relations -
Dr. Robert K. Zeldin M.D.,
Chief Medical Officer -
Dr. Alastair Leighton,
Sr. VP of Manufacturing & Supply Chain -
Tim Randall,
Sr. VP of Risk & Internal Controls -
Joel P. Brooks,
Sr. VP of Fin. -
Christine Elise Sheehy,
Sr. VP of Global Integration -
Dr. Michel Michaelides M.D.,
Head of Clinical Ophthalmology -
Robert J. Wollin J.D.,
Gen. Counsel & Sec. -
& Johnson Innovation Jjdc...,
10% owner -
Advisors Llcperceptive Life...,
-
Katherine Breedis,
Chief Financial Officer -
Life Sciences Master Fund L...,
-
Bruce Gottlieb,
General Counsel -
Advisors Llcedelman Joseph ...,
-
Debra Yu,
-
Robert K Zeldin,
CHIEF MEDICAL OFFICER -
Robert J Wollin,
GENERAL COUNSEL AND SECRETARY